April 12-14, 2023 API CHINA (China International Pharmaceutical Raw Material Trade Fair) was successfully held in Qingdao World Expo City International Exhibition Center, Henan Dongtai Pharmaceutical Co., Ltd. led by chairman Miao Qing sales department, production and technology department, purchasing department, safety and environment department and other nearly 20 people team participated in the exhibition. It is also the company through the United States FDA, EU COS, Japan PMDA, South Korea KFDA and other certifications after the largest number of exhibitors.
Under the leadership of the group company, Dongtai Pharmaceutical has developed a clear product development strategy. The first phase of the non-steroidal anti-inflammatory drug diclofenac sodium series has become the top product of the industry. Now, on the basis of this series of products, the main product is the synthetic camptothecin series. Such as irinotecan hydrochloride, Topotecan hydrochloride, ehitecan mesylate, CDE ring, 7-ethyl-10-hydroxycamptothecin, S-tricyclic amide and so on. In this exhibition, our company has successfully negotiated with a number of well-known drug research and development enterprises in China, and will provide them with key intermediates of ADC drugs for a long time.
At the end of the exhibition, the chairman asked all sales staff to fully integrate into the international pharmaceutical industry chain and strive to build a modern pharmaceutical enterprise integrating apis and preparations.
